177Lu-TLX591
177Lu-TLX591-203
Phase 3 small_molecule active
Quick answer
177Lu-TLX591 for Metastatic Castration-resistant Prostate Cancer is a Phase 3 program (small_molecule) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Telix Pharmaceuticals Ltd
- Indication
- Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active